← Leaderboards
Jiri F Mestecky
University Of Alabama At Birmingham
$6,392,348
Attributed
$6,889,034
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$34,510,157 · 9
By mechanism
U19$15,847,961 · 1
P01$15,755,972 · 4
R01$2,491,972 · 2
R21$314,490 · 1
N01$99,762 · 1
Top collaborators
- Jan Novak3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jan Novak$14,197,925
- Matthew B Renfrow$7,936,462
- Colin Robert Reily$2,556,945
- Bruce A Julian$1,390,994
- Robert P Kimberly$63,455,986
Others in their field
Top investigators on “Glomerulonephritis”
- Ronald J Falk · University Of North Carolina Chapel Hill$19,392,989
- Tanya N. Mayadas · Brigham And Women'S Hospital$18,682,896
- Ali G Gharavi · Mount Sinai School Of Medicine Of Nyu$16,743,333
- Lawrence B. Holzman · University Of Michigan At Ann Arbor$14,822,716
- Gregory S Hageman · University Of Iowa$14,773,700
- Jan Novak · University Of Alabama At Birmingham$12,070,770
Research focus
GlomerulonephritisGalactoseAids VaccinesMucosal ImmunityPolysaccharidesClinical ResearchAntigensImmunoglobulin AMesangial CellIn VivoKidney DiseasesPreventLinkDepositionImmunoglobulin GIga1Antigen-Antibody ComplexBaseAutoantigensAntibodiesAutoimmune DiseasesIga NephropathyIn VitroProperty
Grant awards (28)
IgA Nephropathy: Impact of EBV Infection on Racial Differences$91,740
R21 · FY2023 · AI · contact PI
IgA Nephropathy: Impact of EBV Infection on Racial Differences$222,750
R21 · FY2022 · AI · contact PI
IgA Nephropathy: Interventions with Generation of Nephritogenic Immune Complexes$315,383
R01 · FY2016 · DK · contact PI
IgA Nephropathy: Interventions with Generation of Nephritogenic Immune Complexes$346,150
R01 · FY2015 · DK · contact PI
IgA Nephropathy: Interventions with Generation of Nephritogenic Immune Complexes$331,839
R01 · FY2014 · DK · contact PI
Immunologic Uniqueness of the Female Genital Tract in HIV Pathogenesis$1,982,562
P01 · FY2010 · AI · contact PI
Immunologic Uniqueness of the Female Genital Tract in HIV Pathogenesis$2,000,248
P01 · FY2009 · AI · contact PI
Novel VLP-Based Mucosal and Sytemic HIV Vaccines$127,075
U19 · FY2009 · AI · contact PI
Novel VLP-Based Mucosal and Sytemic HIV Vaccines$3,545,652
U19 · FY2007 · AI · contact PI
Novel VLP-Based Mucosal and Sytemic HIV Vaccines$3,665,980
U19 · FY2006 · AI · contact PI
Familial IgA Nephropathy: Genetic and Metabolic Studies$1,347,130
P01 · FY2006 · DK · contact PI
PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION$291,925
R01 · FY2006 · DE · contact PI
Novel VLP-Based Mucosal and Sytemic HIV Vaccines$3,660,508
U19 · FY2005 · AI
Familial IgA Nephropathy: Genetic and Metabolic Studies$1,347,938
P01 · FY2005 · DK
PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION$298,950
R01 · FY2005 · DE
Novel VLP-Based Mucosal and Sytemic HIV Vaccines$3,273,346
U19 · FY2004 · AI
Familial IgA Nephropathy: Genetic and Metabolic Studies$1,351,361
P01 · FY2004 · DK
PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION$298,950
R01 · FY2004 · DE
Novel VLP-Based Mucosal and Sytemic HIV Vaccines$1,575,400
U19 · FY2003 · AI
Familial IgA Nephropathy: Genetic and Metabolic Studies$1,320,221
P01 · FY2003 · DK
PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION$298,950
R01 · FY2003 · DE
INTEGRATED PRECLINICAL/CLINICAL AIDS VACCINE DEVELOPMENT$1,755,653
P01 · FY2002 · AI
Familial IgA Nephropathy: Genetic and Metabolic Studies$1,311,806
P01 · FY2002 · DK
PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION$309,825
R01 · FY2002 · DE
Biosynthesis and Glycosylation of IgA1 Molecules in IgAN$0
P01 · FY2002 · DK
INTEGRATED PRECLINICAL/CLINICAL AIDS VACCINE DEVELOPMENT$1,735,391
P01 · FY2001 · AI
INTEGRATED PRECLINICAL/CLINICAL AIDS VACCINE DEVELOPMENT$1,603,662
P01 · FY2000 · AI
MUCOSAL IMMUNOLOGY LABORATORY$99,762
N01 · FY2000 · AI